BG64419B1 - Хинолинови и хиноксалинови съединения, които инхибират получените от тромбоцити фактор на растежа и/или р56 iск тирозин кинази - Google Patents

Хинолинови и хиноксалинови съединения, които инхибират получените от тромбоцити фактор на растежа и/или р56 iск тирозин кинази Download PDF

Info

Publication number
BG64419B1
BG64419B1 BG103965A BG10396599A BG64419B1 BG 64419 B1 BG64419 B1 BG 64419B1 BG 103965 A BG103965 A BG 103965A BG 10396599 A BG10396599 A BG 10396599A BG 64419 B1 BG64419 B1 BG 64419B1
Authority
BG
Bulgaria
Prior art keywords
compound
compounds
compound according
tyrosine kinase
cancer
Prior art date
Application number
BG103965A
Other languages
Bulgarian (bg)
English (en)
Other versions
BG103965A (en
Inventor
Michael Myers
Alfred Spada
Paul Persons
Martin Maguire
Original Assignee
Aventis Pharmaceuticals Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharmaceuticals Products Inc. filed Critical Aventis Pharmaceuticals Products Inc.
Publication of BG103965A publication Critical patent/BG103965A/xx
Publication of BG64419B1 publication Critical patent/BG64419B1/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/50—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to ring nitrogen atoms
    • C07D241/52—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/50—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to ring nitrogen atoms
    • C07D241/54—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/06—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing isoquinuclidine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
BG103965A 1997-05-28 1999-12-08 Хинолинови и хиноксалинови съединения, които инхибират получените от тромбоцити фактор на растежа и/или р56 iск тирозин кинази BG64419B1 (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86445597A 1997-05-28 1997-05-28
US97261497A 1997-11-18 1997-11-18

Publications (2)

Publication Number Publication Date
BG103965A BG103965A (en) 2000-07-31
BG64419B1 true BG64419B1 (bg) 2005-01-31

Family

ID=27127839

Family Applications (3)

Application Number Title Priority Date Filing Date
BG103965A BG64419B1 (bg) 1997-05-28 1999-12-08 Хинолинови и хиноксалинови съединения, които инхибират получените от тромбоцити фактор на растежа и/или р56 iск тирозин кинази
BG103963A BG64444B1 (en) 1997-05-28 1999-12-08 QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PATELET-DERIVED GROWTH FACTOR AND/OR p56lck TYROSINE KINASES
BG104006A BG64445B1 (en) 1997-05-28 1999-12-14 QUINOLINE AND QUINOXALINE COMPOUNDS SUPPRESSING THE FACTOR OF GROWTH AND/OR P561ck THYROSINEKINASES SEPARATED FROM THE THROMBOCYTES

Family Applications After (2)

Application Number Title Priority Date Filing Date
BG103963A BG64444B1 (en) 1997-05-28 1999-12-08 QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PATELET-DERIVED GROWTH FACTOR AND/OR p56lck TYROSINE KINASES
BG104006A BG64445B1 (en) 1997-05-28 1999-12-14 QUINOLINE AND QUINOXALINE COMPOUNDS SUPPRESSING THE FACTOR OF GROWTH AND/OR P561ck THYROSINEKINASES SEPARATED FROM THE THROMBOCYTES

Country Status (25)

Country Link
EP (3) EP1001946B1 (fr)
JP (3) JP2002513417A (fr)
KR (2) KR100425638B1 (fr)
CN (3) CN1140516C (fr)
AP (3) AP1444A (fr)
AT (3) ATE286886T1 (fr)
AU (3) AU747026B2 (fr)
BG (3) BG64419B1 (fr)
BR (3) BR9809501A (fr)
CA (3) CA2291728A1 (fr)
CZ (3) CZ298490B6 (fr)
DE (3) DE69828607T2 (fr)
DK (1) DK0991628T3 (fr)
EA (4) EA008136B1 (fr)
ES (1) ES2235331T3 (fr)
HU (2) HUP0002084A3 (fr)
IL (3) IL133009A0 (fr)
NO (3) NO323721B1 (fr)
OA (3) OA11264A (fr)
PL (3) PL194670B1 (fr)
PT (1) PT991628E (fr)
SI (1) SI0991628T1 (fr)
SK (4) SK286084B6 (fr)
UA (1) UA57790C2 (fr)
WO (3) WO1998054157A1 (fr)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180632B1 (en) * 1997-05-28 2001-01-30 Aventis Pharmaceuticals Products Inc. Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
DE69828607T2 (de) * 1997-05-28 2006-01-05 Aventis Pharmaceuticals Inc. CHINOLIN- UND CHINOXALIN-VERBINDUNGEN DIE DEN VON BLUTPLÄTTCHEN ABSTAMMMENDEN WACHSTUMSFAKTOR UND/ODER PDGF- UND P56lck-TYROSIN-KINASE HEMMEN
US6159978A (en) 1997-05-28 2000-12-12 Aventis Pharmaceuticals Product, Inc. Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
US6245760B1 (en) * 1997-05-28 2001-06-12 Aventis Pharmaceuticals Products, Inc Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
GB9904103D0 (en) 1999-02-24 1999-04-14 Zeneca Ltd Quinoline derivatives
US6506769B2 (en) 1999-10-06 2003-01-14 Boehringer Ingelheim Pharmaceuticals, Inc. Heterocyclic compounds useful as inhibitors of tyrosine kinases
US7101869B2 (en) 1999-11-30 2006-09-05 Pfizer Inc. 2,4-diaminopyrimidine compounds useful as immunosuppressants
JP5000068B2 (ja) 2000-08-11 2012-08-15 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド チロシンキナーゼのインヒビターとして有用な複素環化合物
BRPI0308696B8 (pt) 2002-03-27 2021-05-25 Axovant Sciences Gmbh composto derivado de quinolina, seu processo de preparação, sua composição farmacêutica e seus usos
DE10237423A1 (de) * 2002-08-16 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von LCK-Inhibitoren für die Behandlung von immunologischen Erkrankungen
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
PT1558582E (pt) 2003-07-22 2006-05-31 Arena Pharm Inc Derivados de diaril- e aril-heteroaril-ureia como moduladores do receptor de serotonina 5-ht2a uteis para a profilaxia e tratamento de desordens relacionadas com o mesmo
US7432377B2 (en) 2004-01-16 2008-10-07 Wyeth Quinoline intermediates of receptor tyrosine kinase inhibitors and the synthesis thereof
PE20090288A1 (es) 2007-05-10 2009-04-03 Smithkline Beecham Corp Derivados de quinoxalina como inhibidores de la pi3 quinasa
EP2508177A1 (fr) 2007-12-12 2012-10-10 Glaxo Group Limited Associations contenant de la 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
WO2009123714A2 (fr) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Procédés de préparation de dérivés de pyrazole utiles comme modulateurs du récepteur de la sérotonine 5-ht<sb>2a</sb>
WO2010062321A1 (fr) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Procédés utiles pour la préparation de 1-[3-(4-bromo-2-méthyl-2h-pyrazol-3-yl)-4-méthoxy-phényl]-3-(2,4-difluoro‑phényl)-urée, et formes cristallines associées
EP2241557A1 (fr) 2009-04-02 2010-10-20 Æterna Zentaris GmbH Dérivés de chinoxaline et leur utilisation pour le traitement de tumeurs bénignes et malignes
CA2772790C (fr) 2009-09-04 2017-06-27 Benjamin Bader Aminoquinoxalines substituees servant d'inhibiteurs de tyrosine-threonine kinases
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
CN101823998B (zh) * 2010-05-05 2015-03-25 江苏利田科技股份有限公司 一种反应器耦合模拟移动床乙氧基喹啉清洁生产工艺
KR101886459B1 (ko) 2010-10-08 2018-08-07 니발리스 테라퓨틱스, 인코포레이티드 S-나이트로소글루타티온 리덕타제 억제제로서의 신규한 치환된 퀴놀린 화합물
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
JP5898230B2 (ja) 2010-12-16 2016-04-06 ニヴァリス・セラピューティクス・インコーポレーテッド Ｓ−ニトロソグルタチオンレダクターゼ阻害薬としての新規な置換二環芳香族化合物
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
CN104284896B (zh) 2012-03-14 2016-06-01 拜耳知识产权有限责任公司 取代的咪唑并哒嗪
JP6378171B2 (ja) 2012-04-24 2018-08-22 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ｄｎａ−ｐｋ阻害剤
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
ES2704744T3 (es) 2012-06-13 2019-03-19 Incyte Holdings Corp Compuestos tricíclicos sustituidos como inhibidores de FGFR
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
SI3527563T1 (sl) 2013-03-12 2022-01-31 Vertex Pharmaceuticals Incorporated Inhibitorji DNA-PK
EA035095B1 (ru) 2013-04-19 2020-04-27 Инсайт Холдингс Корпорейшн Бициклические гетероциклы в качестве ингибиторов fgfr
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
RS56034B1 (sr) 2013-06-11 2017-09-29 Bayer Pharma AG Derivati prolekova supstituisanih triazolopiridina
RU2675270C2 (ru) 2013-10-17 2018-12-18 Вертекс Фармасьютикалз Инкорпорейтед Сокристаллы и содержащие их фармацевтические композиции
JP6752715B2 (ja) 2014-03-26 2020-09-09 アステックス、セラピューティックス、リミテッドＡｓｔｅｘ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ 組合せ
MX373150B (es) 2014-03-26 2020-04-21 Astex Therapeutics Ltd Combinaciones de un inhibidor del factor de crecimiento de fibroblasto (fgfr) y un inhibidor del receptor del factor de crecimiento 1 similar a insulina (igf1r).
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
TWI719960B (zh) 2015-02-10 2021-03-01 英商阿斯迪克治療公司 新穎組成物
WO2016134294A1 (fr) 2015-02-20 2016-08-25 Incyte Corporation Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
MX373169B (es) 2015-02-20 2020-04-24 Incyte Holdings Corp Heterociclos bicíclicos como inhibidores de receptores del factor de crecimiento fibroblástico (fgfr).
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
WO2016201373A1 (fr) 2015-06-12 2016-12-15 Axovant Sciences Ltd. Dérivés de diaryl et arylhétéroaryl urée utiles pour la prophylaxie et le traitement du trouble du comportement en sommeil rem
WO2017011767A2 (fr) 2015-07-15 2017-01-19 Axovant Sciences Ltd. Dérivés d'arylhérétoaryl urée en tant que modulateurs du récepteur sérotoninergique 5-ht2a utiles pour la prophylaxie et le traitement d'hallucinations associées à une maladie neurodégénérative
WO2017044766A1 (fr) 2015-09-10 2017-03-16 Nivalis Therapeutics, Inc. Formes solides d'un inhibiteur de s-nitrosoglutathione réductase
DK3353177T3 (da) 2015-09-23 2020-08-24 Janssen Pharmaceutica Nv Tricykliske heterocykler til behandling af cancer
AU2016328693B2 (en) 2015-09-23 2021-03-11 Janssen Pharmaceutica Nv Bi-heteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
RU2758669C2 (ru) 2016-09-27 2021-11-01 Вертекс Фармасьютикалз Инкорпорейтед Способ лечения рака с применением сочетания днк-поражающих агентов и ингибиторов днк-пк
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
CR20200590A (es) 2018-05-04 2021-04-26 Incyte Corp Formas sólidas de un inhibidor de fgfr y procesos para prepararlas
MA52493A (fr) 2018-05-04 2021-03-10 Incyte Corp Sels d'un inhibiteur de fgfr
WO2020185532A1 (fr) 2019-03-08 2020-09-17 Incyte Corporation Méthodes de traitement du cancer au moyen d'un inhibiteur de fgfr
WO2021007269A1 (fr) 2019-07-09 2021-01-14 Incyte Corporation Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr
WO2021067374A1 (fr) 2019-10-01 2021-04-08 Incyte Corporation Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr
TWI891666B (zh) 2019-10-14 2025-08-01 美商英塞特公司 作為ｆｇｆｒ抑制劑之雙環雜環
WO2021076728A1 (fr) 2019-10-16 2021-04-22 Incyte Corporation Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr
BR112022010664A2 (pt) 2019-12-04 2022-08-16 Incyte Corp Derivados de um inibidor de fgfr
EP4069696A1 (fr) 2019-12-04 2022-10-12 Incyte Corporation Hétérocycles tricycliques en tant qu'inhibiteurs de fgfr
WO2021146424A1 (fr) 2020-01-15 2021-07-22 Incyte Corporation Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr
TW202304459A (zh) 2021-04-12 2023-02-01 美商英塞特公司 包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法
EP4352059A1 (fr) 2021-06-09 2024-04-17 Incyte Corporation Hétérocycles tricycliques en tant qu'inhibiteurs de fgfr
WO2022261159A1 (fr) 2021-06-09 2022-12-15 Incyte Corporation Hétérocycles tricycliques utiles en tant qu'inhibiteurs de fgfr

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU583793B2 (en) * 1983-07-22 1989-05-11 Du Pont Pharmaceuticals Company Phenylquinolinecarboxylic acids and derivatives as antitumor agents
US4888427A (en) * 1987-04-07 1989-12-19 University Of Florida Amino acids containing dihydropyridine ring systems for site-specific delivery of peptides to the brain
GB9004483D0 (en) 1990-02-28 1990-04-25 Erba Carlo Spa New aryl-and heteroarylethenylene derivatives and process for their preparation
US5480883A (en) * 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5409930A (en) * 1991-05-10 1995-04-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US6177401B1 (en) * 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
NO940245D0 (no) * 1993-01-28 1994-01-24 Takeda Chemical Industries Ltd Quinolin eller quinazolinderivater, deres fremstilling og anvendelse
DE4426373A1 (de) * 1994-07-26 1996-02-01 Bayer Ag 3-Substituierte Chinolin-5-carbonsäurederivate und Verfahren zu ihrer Herstellung
AU3461697A (en) 1996-07-19 1998-02-10 Takeda Chemical Industries Ltd. Heterocyclic compounds, their production and use
NZ336826A (en) * 1997-01-21 2000-06-23 Nissan Chemical Ind Ltd Industrial antimicrobial/mildew-proofing agents, algicides and antifouling agents containing N-quinoxalylanilines
DE69828607T2 (de) * 1997-05-28 2006-01-05 Aventis Pharmaceuticals Inc. CHINOLIN- UND CHINOXALIN-VERBINDUNGEN DIE DEN VON BLUTPLÄTTCHEN ABSTAMMMENDEN WACHSTUMSFAKTOR UND/ODER PDGF- UND P56lck-TYROSIN-KINASE HEMMEN

Also Published As

Publication number Publication date
AP9901709A0 (en) 1999-12-31
EP0991628B1 (fr) 2005-01-12
ATE286886T1 (de) 2005-01-15
HUP0004807A2 (hu) 2001-11-28
EA200100575A1 (ru) 2002-02-28
EA008136B1 (ru) 2007-04-27
AU7707998A (en) 1998-12-30
EP1001946B1 (fr) 2010-12-29
HUP0004807A3 (en) 2001-12-28
NO316377B1 (no) 2004-01-19
CN1261354A (zh) 2000-07-26
CA2291728A1 (fr) 1998-12-03
DE69828607D1 (de) 2005-02-17
NO995819L (no) 1999-11-26
CZ418099A3 (cs) 2000-05-17
DE69842151D1 (de) 2011-04-14
DE69842077D1 (de) 2011-02-10
CZ417999A3 (cs) 2000-05-17
UA57790C2 (uk) 2003-07-15
HK1028042A1 (en) 2001-02-02
AP1554A (en) 2006-01-18
AU747026B2 (en) 2002-05-09
BR9809172A (pt) 2000-08-01
AP9901711A0 (en) 1999-12-31
ATE493389T1 (de) 2011-01-15
EA199901092A1 (ru) 2000-06-26
JP2002500675A (ja) 2002-01-08
EA007807B1 (ru) 2007-02-27
AP1362A (en) 2005-01-19
OA11221A (en) 2003-07-16
SK157999A3 (en) 2000-06-12
AU7706298A (en) 1998-12-30
NO995817L (no) 1999-11-26
SK158099A3 (en) 2000-06-12
EP1001946A1 (fr) 2000-05-24
HUP0002084A3 (en) 2000-12-28
JP2002500676A (ja) 2002-01-08
BR9809501A (pt) 2000-06-20
EP1001946A4 (fr) 2000-07-26
AU751188B2 (en) 2002-08-08
NO995817D0 (no) 1999-11-26
CZ298521B6 (cs) 2007-10-24
CN1261353A (zh) 2000-07-26
NO995818L (no) 1999-11-26
AP1444A (en) 2005-07-18
BG103965A (en) 2000-07-31
EP1001945B1 (fr) 2011-03-02
EP1001945A1 (fr) 2000-05-24
AU7803798A (en) 1998-12-30
AU751188C (en) 2005-06-30
EA004103B1 (ru) 2003-12-25
EP0991628A4 (fr) 2000-07-26
CN1140516C (zh) 2004-03-03
SI0991628T1 (en) 2005-06-30
NO995818D0 (no) 1999-11-26
BG104006A (en) 2000-07-31
CZ296845B6 (cs) 2006-07-12
DK0991628T3 (da) 2005-05-17
IL133007A (en) 2005-06-19
CZ415899A3 (cs) 2000-05-17
CA2291774A1 (fr) 1998-12-03
SK158199A3 (en) 2000-06-12
EP1001945A4 (fr) 2000-07-26
CA2291750A1 (fr) 1998-12-03
EA002600B1 (ru) 2002-06-27
BR9809515A (pt) 2000-06-20
WO1998054157A1 (fr) 1998-12-03
KR20010013057A (ko) 2001-02-26
PL194670B1 (pl) 2007-06-29
IL133007A0 (en) 2001-03-19
KR20010039512A (ko) 2001-05-15
ES2235331T3 (es) 2005-07-01
AU742739B2 (en) 2002-01-10
IL133008A0 (en) 2001-03-19
EA199901086A1 (ru) 2000-06-26
PL337087A1 (en) 2000-07-31
PL194980B1 (pl) 2007-07-31
PL337086A1 (en) 2000-07-31
WO1998054158A1 (fr) 1998-12-03
KR100440756B1 (ko) 2004-07-21
AP9901710A0 (en) 1999-12-31
JP2002513417A (ja) 2002-05-08
BG103963A (en) 2000-07-31
EA199901090A1 (ru) 2000-08-28
EP0991628A1 (fr) 2000-04-12
WO1998054156A1 (fr) 1998-12-03
CN1280572A (zh) 2001-01-17
PL195552B1 (pl) 2007-10-31
IL133009A0 (en) 2001-03-19
SK286084B6 (sk) 2008-03-05
BG64445B1 (en) 2005-02-28
PL337084A1 (en) 2000-07-31
PT991628E (pt) 2005-05-31
NO323721B1 (no) 2007-06-25
NO995819D0 (no) 1999-11-26
BG64444B1 (en) 2005-02-28
NO323720B1 (no) 2007-06-25
KR100425638B1 (ko) 2004-04-03
OA11222A (en) 2003-07-16
HUP0002084A2 (hu) 2000-10-28
CZ298490B6 (cs) 2007-10-17
OA11264A (en) 2002-11-19
DE69828607T2 (de) 2006-01-05
ATE500233T1 (de) 2011-03-15

Similar Documents

Publication Publication Date Title
BG64419B1 (bg) Хинолинови и хиноксалинови съединения, които инхибират получените от тромбоцити фактор на растежа и/или р56 iск тирозин кинази
CN100390155C (zh) 喹啉和喹喔啉化合物
SK9052001A3 (en) Quinoline and quinoxaline compounds as pdgf-r and/or lck tyrosine kinase inhibitors
MXPA99011026A (en) Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
KR100480360B1 (ko) 혈소판-유도된 성장 인자 및/또는 ｐ56ｌｃｋ 티로신 키나제를 억제하는 퀴놀린 및 퀴녹살린 화합물
MXPA01005319A (en) Quinoline and quinoxaline compounds
HK1028042B (en) Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56 lck tyrosine kinases
HUP0002219A2 (hu) Vérlemezke-eredetű növekedési faktor és/vagy p56lck tirozin kináz gátló hatású kinolin és kinoxalinszármazékok, valamint ezeket a vegyületeket tartalmazó gyógyászati készítmények